Oscotec applies for U.S. clinical 2a IND of its rheumatoid arthritis treatment
Oscotec(CEo Jung-Geun Kim), a new drug developing company, announced on the 26th that the company applied for a IND for a clinical 2a study to the U.S. FDA as completing Phase I SAD(single ascending dose) & MAD(multiple ascending dose) studies of ‘SKI-O-703,’ a new drug candidate which selectivel...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
